Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Renaissance Group LLC

Renaissance Group LLC increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 11.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 11,523 shares of the company's stock after acquiring an additional 1,168 shares during the period. Renaissance Group LLC's holdings in Medpace were worth $3,828,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Benjamin Edwards Inc. grew its position in shares of Medpace by 232.0% during the 3rd quarter. Benjamin Edwards Inc. now owns 1,142 shares of the company's stock worth $381,000 after buying an additional 798 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Medpace during the 3rd quarter worth approximately $374,000. State Street Corp increased its position in shares of Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after acquiring an additional 50,312 shares during the period. Wellington Management Group LLP increased its holdings in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Medpace by 75.1% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 949 shares of the company's stock worth $317,000 after buying an additional 407 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on MEDP shares. Mizuho lowered their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and set a $328.00 price target on the stock. in a research note on Monday. Truist Financial lowered their price objective on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research report on Thursday. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Ten investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Medpace has an average rating of "Hold" and an average price target of $357.50.

Medpace Stock Up 1.8 %

MEDP traded up $5.39 on Monday, hitting $303.11. 186,880 shares of the company traded hands, compared to its average volume of 319,076. The stock has a market capitalization of $9.16 billion, a PE ratio of 24.00, a PEG ratio of 3.81 and a beta of 1.46. The company has a 50 day moving average of $323.58 and a 200-day moving average of $334.47. Medpace Holdings, Inc. has a 12-month low of $272.00 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.